The Vanguard Group, Inc. has recently announced that it has increased stake in Perspective Therapeutics Inc (AMEX:CATX) by 0.78%. After grabbing 12.74 million shares, the institutional investor is now in possession of 99189.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 4.54% having worth around $3.25 million. Moreover, Baker Bros. Advisors LP increased its share by 5.32 million to have a control over 7.64 million shares. And Geode Capital Management LLC raised its holdings to 66750.0 shares by acquiring 2.52 million shares or 0.90% of the stake.
Perspective Therapeutics Inc (CATX) concluded trading on 12/28/23 at a closing price of $0.46, with 2.28 million shares of worth about $1.05 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -31.48% during that period and on Thursday the price saw a loss of about -4.17%. Currently the company’s common shares owned by public are about 280.57M shares, out of which, 202.38M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 2 analysts are covering the CATX stock and their offered price forecasts bring an average price target of $1.30. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $1.40 and could fall to a lowest price of $1.20. The stock’s current price level is 64.62% above of average price target set by the analysts, while a rise to estimated low would result in gain of 61.67% for the stock. However, touching the estimated high of $1.40 would mean a gain of 67.14% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 2 times over the past 12 months. They bought 187,500 shares in 2 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Vanguard Total Stock Market ETF, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu are the top 3 mutual funds which are holding stakes in Perspective Therapeutics Inc Vanguard Total Stock Market ETF is currently holding 9.67 million shares of worth totaling $2.47 million. The company recently came buying 0.0 shares which brought its stake up to 3.45% of the company’s outstanding shares. Vanguard Extended Market Index Fu bought 60727.0 shares, after which its hold over company’s outstanding shares expand to 0.99%, leaving 2.77 million shares with the mutual fund that have a worth of about $0.71 million. Fidelity Extended Market Index Fu, after buying 1.46 million shares, have now control over 0.52% of the stake in the company. It holds 0.0 shares of worth $0.37 million.
Perspective Therapeutics Inc (AMEX: CATX) started trading at $0.50, above $0.03 from concluding price of the previous day. However, the stock later moved at a day high price of 0.4999, or with a loss of -4.17%. Stock saw a price change of 33.04% in past 5 days and over the past one month there was a price change of 79.28%. Year-to-date (YTD), CATX shares are showing a performance of 84.14% which increased to 76.36% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.20 but also hit the highest price of $0.73 during that period. The average intraday trading volume for Perspective Therapeutics Inc shares is 398.08K. The stock is currently trading 53.88% above its 20-day simple moving average (SMA20), while that difference is up 64.79% for SMA50 and it goes to -1.36% lower than SMA200.
The Vanguard Group, Inc. acquired 12.74 million shares of Perspective Therapeutics Inc having value of about $3.25 million. Data submitted at the U.S SEC by The Vanguard Group, Inc. revealed that the firm now holds 99189.0 shares in the company valued at close to $45626.94, or have control over 0.78% stake in the company. Perspective Therapeutics Inc (AMEX: CATX) currently have 280.57M outstanding shares and institutions hold larger chunk of about 13.04% of that. Holding of mutual funds in the company is about 5.59% while other institutional holders and individual stake holders have control over 7.46% and 1.97% of the stake respectively.
The stock has a current market capitalization of $127.66M and its 3Y-monthly beta is at 1.69. It has posted earnings per share of -$0.09 in the same period. It has Quick Ratio of 2.55 while making debt-to-equity ratio of 0.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CATX, volatility over the week remained 12.85% while standing at 10.47% over the month.
Analysts are in expectations that Perspective Therapeutics Inc (CATX) stock would likely to be making an EPS of -$0.04 in the current quarter, while forecast for next quarter EPS is -$0.03 and it is $0 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.04 which is -$0.04 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.02 in the same quarter a year ago.
Analysts at 2 brokerage firms have issued recommendations for the Perspective Therapeutics Inc (CATX)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.00. Out of those 2 Wall Street analysts, 2 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
